Analysed PRECISION BIOSCIENCES INC (DTIL:NASDAQ) News Sources
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
28-04-2026
yahoo.com
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
29-04-2026
yahoo.com
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
30-04-2026
yahoo.com
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
05-05-2026
yahoo.com
Bullish: Analysts Just Made A Notable Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts
13-05-2026
yahoo.com
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
14-05-2026
yahoo.com
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
21-05-2026
yahoo.com
What is the current price of PRECISION BIOSCIENCES INC (DTIL:NASDAQ)?
The current price of PRECISION BIOSCIENCES INC (DTIL:NASDAQ) is $6.11.
PRECISION BIOSCIENCES INC (DTIL:NASDAQ) absolute price change since previous trading day?
The absolute price change of PRECISION BIOSCIENCES INC (DTIL:NASDAQ) since the previous trading day is $-0.06.
PRECISION BIOSCIENCES INC (DTIL:NASDAQ) percentage price change since previous trading day?
The percentage price change of PRECISION BIOSCIENCES INC (DTIL:NASDAQ) since the previous trading day is -0.9724%.
What is the most recent average sentiment score for PRECISION BIOSCIENCES INC (DTIL:NASDAQ)?
The most recent average sentiment score for PRECISION BIOSCIENCES INC (DTIL:NASDAQ) is 63 out of 100.
What is the most recent average sentiment for PRECISION BIOSCIENCES INC (DTIL:NASDAQ)?
The most recent sentiment for PRECISION BIOSCIENCES INC (DTIL:NASDAQ) is .
SEC-8K** Filing Available For PRECISION BIOSCIENCES INC (DTIL:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.